estradiol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
estrogens 1057 50-28-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • estradiol
  • 17Beta-Estradiol
  • 17Beta-Oestradiol
  • Beta-Estradiol
  • estradiol hemihydrate
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
  • Molecular weight: 272.39
  • Formula: C18H24O2
  • CLOGP: 3.78
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS: -4.11
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 mg N
2 mg O
1 mg P
0.30 mg P
5 mg R
50 mcg TD
1 mg TD
1.53 mg TD
25 mcg V
7.50 mcg V

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.09 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.84 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 23, 1975 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product adhesion issue 2742.77 34.30 422 2983 830 2353850
Hot flush 1130.15 34.30 265 3140 6934 2347746
Drug ineffective 984.92 34.30 447 2958 101177 2253503
Application site rash 701.08 34.30 119 3286 500 2354180
Vulvovaginal discomfort 555.46 34.30 96 3309 457 2354223
Application site pruritus 535.67 34.30 100 3305 786 2353894
Product quality issue 526.29 34.30 158 3247 10671 2344009
Application site erythema 523.05 34.30 104 3301 1176 2353504
Vulvovaginal pain 374.62 34.30 67 3338 400 2354280
Vaginal discharge 315.73 34.30 65 3340 880 2353800
Breast cancer 312.19 34.30 103 3302 9392 2345288
Vaginal haemorrhage 295.39 34.30 85 3320 4895 2349785
Application site irritation 288.49 34.30 54 3351 428 2354252
Meningioma 266.34 34.30 53 3352 597 2354083
Pulmonary embolism 207.65 34.30 91 3314 17992 2336688
Vulvovaginal dryness 205.55 34.30 40 3365 397 2354283
Night sweats 204.08 34.30 59 3346 3441 2351239
Breast tenderness 199.22 34.30 41 3364 552 2354128
Vulvovaginal burning sensation 194.46 34.30 38 3367 386 2354294
Feeling abnormal 190.56 34.30 93 3312 23488 2331192
Wrong technique in product usage process 187.38 34.30 87 3318 19661 2335019
Product substitution issue 170.36 34.30 56 3349 5013 2349667
Application site reaction 158.87 34.30 31 3374 312 2354368
Rash 157.42 34.30 114 3291 59444 2295236
Application site pain 150.86 34.30 39 3366 1487 2353193
Application site burn 150.62 34.30 28 3377 212 2354468
Headache 149.99 34.30 125 3280 80054 2274626
Application site vesicles 146.41 34.30 30 3375 394 2354286
Vaginal infection 144.63 34.30 34 3371 868 2353812
Menopausal symptoms 143.94 34.30 29 3376 348 2354332
Product complaint 143.92 34.30 48 3357 4490 2350190
Depression 123.30 34.30 74 3331 28058 2326622
Incorrect dose administered 121.57 34.30 52 3353 9643 2345037
Insomnia 113.40 34.30 68 3337 25719 2328961
Vaginal odour 110.76 34.30 20 3385 126 2354554
Migraine 110.47 34.30 50 3355 10603 2344077
Fungal infection 109.83 34.30 40 3365 4849 2349831
Vulvovaginal pruritus 106.12 34.30 24 3381 513 2354167
Product physical issue 105.60 34.30 27 3378 983 2353697
Anxiety 105.28 34.30 68 3337 29291 2325389
Vulvovaginal mycotic infection 104.63 34.30 26 3379 842 2353838
Skin irritation 92.58 34.30 26 3379 1359 2353321
Underdose 87.53 34.30 36 3369 6042 2348638
Product use in unapproved indication 86.72 34.30 43 3362 11157 2343523
Deep vein thrombosis 86.58 34.30 45 3360 12887 2341793
Hypersensitivity 85.39 34.30 55 3350 23538 2331142
Off label use 85.21 34.30 88 3317 73510 2281170
Application site urticaria 83.55 34.30 15 3390 91 2354589
Blood oestrogen decreased 81.48 34.30 14 3391 63 2354617
Postmenopausal haemorrhage 81.47 34.30 19 3386 467 2354213
Pruritus 79.46 34.30 67 3338 43273 2311407
Drug hypersensitivity 79.20 34.30 69 3336 46574 2308106
Breast cancer female 79.02 34.30 23 3382 1367 2353313
Nasal polyps 78.79 34.30 16 3389 200 2354480
Mood swings 78.09 34.30 28 3377 3241 2351439
Abdominal distension 77.73 34.30 39 3366 10372 2344308
Embolism venous 77.00 34.30 17 3388 324 2354356
Hyperhidrosis 76.46 34.30 44 3361 15378 2339302
Muscle spasms 74.89 34.30 49 3356 21517 2333163
Nausea 74.66 34.30 101 3304 112088 2242592
Salpingo-oophorectomy unilateral 74.65 34.30 11 3394 12 2354668
Respiratory symptom 72.22 34.30 15 3390 211 2354469
Product use issue 71.99 34.30 39 3366 12130 2342550
Endometrial cancer stage I 71.18 34.30 12 3393 47 2354633
Endometrial cancer 71.09 34.30 18 3387 629 2354051
Breast mass 69.93 34.30 20 3385 1116 2353564
Sputum increased 69.69 34.30 14 3391 165 2354515
Weight increased 68.53 34.30 47 3358 22290 2332390
Metrorrhagia 68.32 34.30 23 3382 2206 2352474
Pain 67.98 34.30 72 3333 61785 2292895
Application site scar 67.09 34.30 12 3393 71 2354609
Product odour abnormal 64.49 34.30 15 3390 364 2354316
Alopecia 64.45 34.30 45 3360 21956 2332724
Hysterectomy 62.45 34.30 20 3385 1640 2353040
Inappropriate schedule of product administration 60.95 34.30 35 3370 12169 2342511
Urticaria 60.50 34.30 45 3360 24216 2330464
Vaginal erosion 59.77 34.30 10 3395 37 2354643
Uterine leiomyoma 59.70 34.30 19 3386 1526 2353154
Ovarian hyperstimulation syndrome 59.67 34.30 16 3389 702 2353978
Breast cancer in situ 59.38 34.30 14 3391 361 2354319
Chronic sinusitis 58.54 34.30 15 3390 550 2354130
Sinusitis fungal 57.86 34.30 11 3394 95 2354585
Breast pain 57.72 34.30 18 3387 1353 2353327
Hormone level abnormal 56.81 34.30 14 3391 437 2354243
Irritability 56.71 34.30 27 3378 6400 2348280
Diastolic dysfunction 56.68 34.30 15 3390 625 2354055
Female genital tract fistula 55.74 34.30 14 3391 473 2354207
Butterfly rash 55.64 34.30 12 3393 204 2354476
Oestrogen receptor assay positive 55.28 34.30 11 3394 123 2354557
Application site erosion 53.97 34.30 10 3395 74 2354606
Dizziness 53.55 34.30 62 3343 58603 2296077
Chest pain 52.51 34.30 44 3361 28093 2326587
Dyspareunia 52.50 34.30 13 3392 414 2354266
Dyspnoea 52.38 34.30 71 3334 78662 2276018
Application site inflammation 52.13 34.30 10 3395 91 2354589
Malaise 51.15 34.30 59 3346 55526 2299154
Breast enlargement 49.12 34.30 12 3393 361 2354319
Abdominal pain 48.71 34.30 46 3359 34328 2320352
Fibrocystic breast disease 48.49 34.30 11 3394 238 2354442
Diverticulum 48.25 34.30 16 3389 1463 2353217
Chest discomfort 47.80 34.30 32 3373 14563 2340117
Incorrect dose administered by product 47.73 34.30 8 3397 30 2354650
Maternal exposure during pregnancy 47.27 34.30 32 3373 14831 2339849
Fatigue 46.81 34.30 70 3335 84803 2269877
Progesterone receptor assay positive 46.71 34.30 9 3396 84 2354596
Hiatus hernia 46.57 34.30 17 3388 2067 2352613
Head discomfort 46.53 34.30 16 3389 1635 2353045
Tricuspid valve incompetence 46.48 34.30 16 3389 1640 2353040
Therapeutic product effect decreased 46.14 34.30 28 3377 10761 2343919
Obstructive airways disorder 45.38 34.30 15 3390 1358 2353322
Endometrial hypertrophy 44.65 34.30 9 3396 108 2354572
Emphysema 44.64 34.30 14 3391 1071 2353609
Abdominal pain lower 44.34 34.30 18 3387 2915 2351765
Poor quality product administered 43.94 34.30 13 3392 817 2353863
Discomfort 43.46 34.30 21 3384 5138 2349542
Osteoporosis 43.43 34.30 20 3385 4394 2350286
Endometrial hyperplasia 43.13 34.30 10 3395 239 2354441
Eczema 42.80 34.30 18 3387 3187 2351493
Therapeutic response unexpected 42.77 34.30 19 3386 3840 2350840
Sleep apnoea syndrome 42.58 34.30 16 3389 2110 2352570
Gastrooesophageal reflux disease 42.52 34.30 25 3380 9070 2345610
Ophthalmic vein thrombosis 42.48 34.30 7 3398 23 2354657
Bacterial vulvovaginitis 42.30 34.30 9 3396 143 2354537
Emotional disorder 42.21 34.30 16 3389 2161 2352519
Erythema 42.15 34.30 37 3368 25122 2329558
Drug level decreased 41.93 34.30 13 3392 958 2353722
Tinnitus 40.55 34.30 20 3385 5115 2349565
Breast conserving surgery 40.44 34.30 9 3396 178 2354502
Uterine haemorrhage 40.44 34.30 12 3393 762 2353918
Blood oestrogen increased 40.13 34.30 7 3398 35 2354645
Condition aggravated 40.04 34.30 40 3365 31939 2322741
Nipple pain 39.38 34.30 8 3397 100 2354580
Iron deficiency anaemia 39.16 34.30 15 3390 2084 2352596
Breast disorder 38.65 34.30 10 3395 381 2354299
Oestradiol increased 38.50 34.30 7 3398 46 2354634
Disease recurrence 38.27 34.30 17 3388 3434 2351246
Candida infection 37.91 34.30 16 3389 2857 2351823
Ventricular dyskinesia 37.87 34.30 7 3398 51 2354629
Feeling hot 37.62 34.30 21 3384 6907 2347773
Osteoarthritis 37.57 34.30 21 3384 6925 2347755
Cor pulmonale acute 37.52 34.30 7 3398 54 2354626
Application site discolouration 37.49 34.30 9 3396 251 2354429
Periorbital oedema 37.20 34.30 12 3393 1006 2353674
Right ventricular dilatation 36.86 34.30 7 3398 60 2354620
Dermatitis contact 36.67 34.30 13 3392 1453 2353227
Vaginal laceration 36.66 34.30 7 3398 62 2354618
Skin burning sensation 36.57 34.30 14 3391 1942 2352738
Wheezing 36.44 34.30 20 3385 6364 2348316
Product packaging issue 36.06 34.30 9 3396 296 2354384
Product size issue 35.81 34.30 8 3397 161 2354519
Application site discharge 35.62 34.30 7 3398 73 2354607
Palpitations 35.44 34.30 28 3377 16428 2338252
Application site dermatitis 34.65 34.30 7 3398 85 2354595
Vaginal disorder 34.59 34.30 8 3397 189 2354491

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC G03CA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ESTROGENS
Natural and semisynthetic estrogens, plain
ATC G03AA14 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA17 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AB08 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03CA53 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ESTROGENS
Natural and semisynthetic estrogens, plain
FDA CS M0447348 Estradiol Congeners
FDA EPC N0000175825 Estrogen
FDA MoA N0000000100 Estrogen Receptor Agonists
MeSH PA D004967 Estrogens
MeSH PA D006728 Hormones

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Premenstrual dysphoric disorder indication 596004
Contraception indication 13197004
Female hypogonadism syndrome indication 16041008
Atrophic vaginitis indication 52441000
Urethral atrophy indication 52620003
Primary ovarian failure indication 65846009
Acne vulgaris indication 88616000
Postmenopausal osteoporosis indication 102447009
Menopausal flushing indication 198436008
Atrophic vulva indication 248861000 DOID:14275
Advanced Prostatic Carcinoma indication
Metastatic Breast Carcinoma indication
Metastatic Prostate Carcinoma indication
Amenorrhea off-label use 14302001 DOID:13938
Polycystic ovaries off-label use 69878008
Dysmenorrhea off-label use 266599000
Postcoital contraception off-label use 268463003
Abnormal uterine bleeding unrelated to menstrual cycle off-label use 312984006
Menorrhagia off-label use 386692008
Pre-Menopausal Osteoporosis off-label use
Heart valve disorder contraindication 368009 DOID:4079
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Gynecomastia contraindication 4754008 DOID:12698
Hypocalcemia contraindication 5291005
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Toxic shock syndrome contraindication 18504008 DOID:14115
Myocardial infarction contraindication 22298006 DOID:5844
Fibroadenosis of breast contraindication 23260002 DOID:10352
Diplopia contraindication 24982008
Retinal hemorrhage contraindication 28998008
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Heart disease contraindication 56265001 DOID:114
Anorexia nervosa contraindication 56882008 DOID:8689
Benign mammary dysplasia contraindication 57993004
Acute nephropathy contraindication 58574008
Obstructive hyperbilirubinemia contraindication 59848001
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Thrombophlebitis contraindication 64156001 DOID:3875
Osteoporosis contraindication 64859006 DOID:11476
Intermenstrual bleeding - irregular contraindication 64996003
Hypercalcemia contraindication 66931009 DOID:12678
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Uterine leiomyoma contraindication 95315005 DOID:13223
Neoplasm of prostate contraindication 126906006 DOID:10283
Neoplasm of female genital organ contraindication 126907002 DOID:120
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Endometriosis contraindication 129103003
Bed-ridden contraindication 160685001
Liver function tests abnormal contraindication 166603001
Mammography abnormal contraindication 168750009
Angina pectoris contraindication 194828000
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Metabolic syndrome X contraindication 237602007 DOID:14221
Endometrial carcinoma contraindication 254878006 DOID:2871
Benign prostatic hyperplasia contraindication 266569009
Edema contraindication 267038008
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Osteopenia contraindication 312894000
Functional visual loss contraindication 313165001
Non-Q wave myocardial infarction contraindication 314207007
Malignant tumor of cervix contraindication 363354003 DOID:4362
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Resistance to activated protein C due to Factor V Leiden contraindication 421527008
Optic disc edema contraindication 423341008 DOID:146
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Diabetes with Vascular Disease Complication contraindication
Breast Carcinoma in Males contraindication
Acute Thromboembolic Stroke contraindication
Major Surgery with Prolonged Post-Operative Immobilization contraindication
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication
Worsening Headache Disorder contraindication
Benign Hepatic Cell Adenoma contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.13 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1MG,1MG PREFEST TEVA WOMENS N021040 Oct. 22, 1999 DISCN TABLET ORAL 6747019 March 20, 2020 HORMONE REPLACEMENT
1MG,1MG PREFEST TEVA WOMENS N021040 Oct. 22, 1999 DISCN TABLET ORAL 7320970 March 30, 2020 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
10MCG VAGIFEM NOVO NORDISK INC N020908 Nov. 25, 2009 RX TABLET VAGINAL 7018992 Sept. 17, 2022 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
0.025MG/24HR MINIVELLE NOVEN N203752 Sept. 23, 2014 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.0375MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.05MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.075MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.1MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 10206932 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 8846648 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 8846649 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9006222 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9114145 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9114146 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9301920 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL May 29, 2021 NEW PRODUCT
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL May 29, 2021 NEW PRODUCT
1MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL Oct. 28, 2021 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor AGONIST EC50 10.30 WOMBAT-PK CHEMBL
Calcium-activated potassium channel subunit alpha-1 Ion channel ACTIVATOR EC50 5.60 IUPHAR
Sodium-dependent serotonin transporter Transporter Ki 5.24 DRUG MATRIX
Glucocorticoid receptor Nuclear hormone receptor Ki 4.73 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 4.93 DRUG MATRIX
Steroid hormone receptor ERR2 Nuclear hormone receptor IC50 8.49 CHEMBL
Steroid hormone receptor ERR1 Nuclear hormone receptor IC50 8.44 CHEMBL
Sex hormone-binding globulin Secreted Kd 8.83 CHEMBL
Steryl-sulfatase Enzyme IC50 4.08 CHEMBL
Androgen receptor Nuclear hormone receptor IC50 7.72 CHEMBL
G-protein coupled estrogen receptor 1 GPCR EC50 9.52 WOMBAT-PK
Estrogen receptor beta Nuclear hormone receptor EC50 9.70 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 6.54 WOMBAT-PK
Corticosteroid-binding globulin Secreted Ki 5 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.95 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.37 DRUG MATRIX
Estrogen receptor Transcription factor IC50 9.45 CHEMBL
Estrogen receptor Transcription factor IC50 8.72 CHEMBL
Estrogen receptor Transcription factor IC50 8.66 CHEMBL
Estrogen receptor beta Transcription factor IC50 8.77 CHEMBL
Androgen receptor Transcription factor IC50 6.39 CHEMBL
Estrogen receptor beta Transcription factor IC50 8.64 CHEMBL

External reference:

IDSource
D004958 MESH_DESCRIPTOR_UI
4021205 VUID
N0000148651 NUI
C0014912 UMLSCUI
D00105 KEGG_DRUG
4TI98Z838E UNII
406 INN_ID
126172005 SNOMEDCT_US
12839006 SNOMEDCT_US
6157 MMSL
4083 RXNORM
4684 MMSL
d00537 MMSL
8602 MMSL
4017609 VANDF
4021205 VANDF
73244 MMSL
001265 NDDF
35380-71-3 SECONDARY_CAS_RN
CHEBI:16469 CHEBI
CHEMBL135 ChEMBL_ID
DB00783 DRUGBANK_ID
EST PDB_CHEM_ID
5757 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Estring HUMAN PRESCRIPTION DRUG LABEL 1 0013-2150 RING 2 mg VAGINAL NDA 16 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5885 PATCH 0.03 mg TRANSDERMAL NDA 14 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5886 PATCH 0.05 mg TRANSDERMAL NDA 14 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5887 PATCH 0.08 mg TRANSDERMAL NDA 14 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5888 PATCH 0.10 mg TRANSDERMAL NDA 14 sections
ELESTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0037-4801 GEL, METERED 0.52 mg TOPICAL NDA 20 sections
ELESTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0037-4802 GEL, METERED 0.52 mg TOPICAL NDA 20 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0343 PATCH, EXTENDED RELEASE 0.04 mg TRANSDERMAL NDA 21 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0344 PATCH, EXTENDED RELEASE 0.05 mg TRANSDERMAL NDA 21 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0345 PATCH, EXTENDED RELEASE 0.08 mg TRANSDERMAL NDA 21 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0346 PATCH, EXTENDED RELEASE 0.10 mg TRANSDERMAL NDA 21 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0365 PATCH, EXTENDED RELEASE 0.03 mg TRANSDERMAL NDA 21 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0093-3223 INSERT 10 ug VAGINAL ANDA 19 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0093-3541 CREAM 0.10 mg VAGINAL ANDA 15 sections
Mimvey HUMAN PRESCRIPTION DRUG LABEL 2 0093-5455 TABLET, FILM COATED 1 mg ORAL ANDA 20 sections
Estradiol Vaginal HUMAN PRESCRIPTION DRUG LABEL 1 0115-1518 CREAM 0.10 mg VAGINAL ANDA 14 sections
Vagifem HUMAN PRESCRIPTION DRUG LABEL 1 0169-5176 INSERT 10 ug VAGINAL NDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0179-1999 TABLET 0.50 mg ORAL ANDA 11 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-1452 TABLET 0.50 mg ORAL ANDA 13 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-1454 TABLET 1 mg ORAL ANDA 13 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-1458 TABLET 2 mg ORAL ANDA 13 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3349 PATCH 0.03 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3350 PATCH 0.05 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3351 PATCH 0.08 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3352 PATCH 0.10 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3360 PATCH 0.04 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3361 PATCH 0.06 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4619 PATCH 0.03 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4620 PATCH 0.04 mg TRANSDERMAL ANDA 20 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4621 PATCH 0.05 mg TRANSDERMAL ANDA 20 sections